Interpretation: This pilot study highlighted the potential of next-generation sequencing to deliver molecular diagnoses rapidly with a high success rate. With broader use, this approach has the potential to alter health care delivery in the NICU.
A rare disease is defined by a prevalence of less than 1 in 2000 individuals. 1 How ever, when considered in aggregate, 1%-2% of Canadians will manifest a rare dis ease in their lifetime. 2, 3 These disorders can pres ent in the newborn period, and a third of these young children will succumb to the disease in their first year of life. [3] [4] [5] Newborns who present with rare diseases typically require admission to a neonatal intensive care unit (NICU), where the standard of care includes exhaustive consulta tions and investigations to determine a molecular diagnosis. Reaching such a diagnosis is a chal lenge, given the considerable clinical and genetic heterogeneity associated with rare diseases; diagnosis is also confounded by the early stage of presentation, which is further accentuated in premature newborns. As a result, traditional genetic or metabolic investigations can be lengthy and expensive, and they often fail to arrive at a diagnosis in a timely manner. 6 The current approach during a medical gen etics consultation begins with a clinical assess ment, followed by diagnostic testing that usually includes sequential testing of one or more candi date genes or panels of candidate genes. This step often requires approval for outofcountry testing, as only a limited number of gene tests are available for clinical testing in Canada. If the result of the first test is negative, the clinician may consider testing the next most likely candi date gene, frequently with diminishing returns. This approach can take months or years and can be a frustrating process for the patient, family Background: Rare diseases often present in the first days and weeks of life and may require complex management in the setting of a neonatal intensive care unit (NICU). Exhaustive consultations and traditional genetic or metabolic investigations are costly and often fail to arrive at a final diagnosis when no recognizable syndrome is suspected. For this pilot project, we assessed the feasibility of next-generation sequencing as a tool to improve the diagnosis of rare diseases in newborns in the NICU.
Methods:
We retrospectively identified and prospectively recruited newborns and infants admitted to the NICU of the Children's Hospital of Eastern Ontario and the Ottawa Hospital, General Campus, who had been referred to the medical genetics or metabolics inpatient consult service and had features suggesting an underlying genetic or metabolic condition. DNA from the newborns and parents was enriched for a panel of clinically relevant genes and sequenced on a MiSeq sequencing platform (Illumina Inc.). The data were interpreted with a standard informatics pipeline and reported to care providers, who assessed the importance of genotype-phenotype correlations.
Results: Of 20 newborns studied, 8 received a diagnosis on the basis of next-generation sequencing (diagnostic rate 40%). The diagnoses were renal tubular dysgenesis, SCN1A-related encephalopathy syndrome, myotubular myo pathy, FTO deficiency syndrome, cranioectodermal dysplasia, congenital myasthenic syndrome, autosomal dominant intellectual disability syndrome type 7 and Denys-Drash syndrome.
and clinicians providing care. 7 The inability to arrive at a timely and efficient diagnosis repre sents a substantial lost opportunity, as a diagno sis can limit or even halt further invasive, and at times futile, investigations for the neonate. Importantly, an accurate diagnosis informs prog nosis and may guide management decisions.
The advent of nextgeneration sequencing has greatly advanced the ability to rapidly identify the novel genes responsible for disease. 8 Whole exome sequencing (sequencing of the coding portion of the genome) is beginning to be used on a clinical basis in tertiary care centres. 9, 10 In these initial clinical cohort studies, a molecular diagnosis was provided by wholeexome sequencing for about 25% of families. The pro portion increased to 31% when the patient's par ents were also analyzed. 9 Another study used retro spective wholegenome sequencing to make a diagnosis in 57% of 35 children from the inten sive care setting.
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Although wholeexome and wholegenome sequencing are powerful tools, important condi tions are required for translation of these meth ods to the clinic or hospital setting. The avail ability of highthroughput sequencers, complex and costly infrastructure, and personnel with bioinformatics expertise are prerequisites. These resources may not be broadly available within some health care systems, and other strategies may be more relevant and effective.
Another attractive alternative is analysis based on nextgeneration sequencing that focuses only on the clinically relevant genes with known associated clinical phenotypes. 12 This strategy offers several advantages over wholeexome or wholegenome sequencinginterpretation of variants may be more straight forward, a higher depth of coverage can be read ily achieved, and less infrastructure and fewer personnel are required -all of which contribute to a more rapid return of results.
For this pilot study, we evaluated the perform ance of a targeted nextgeneration sequencing panel that included 4813 "diseaserelevant" genes in a cohort of newborns with rare disease in the NICU and assessed the effectiveness of this method to accurately diagnose these critically ill babies. We identified the patients retrospectively (i.e., after discharge from the NICU) or prospectively (i.e., during the NICU admission). The inclusion criteria were any newborn or infant with a cur rently undiagnosed complex medical presentation who had been, or was currently, admitted to the NICU and had been referred to the medical genetics or metabolics inpatient consult service of the study hospitals. Included neonates had to have at least one of the following findings: one or more congenital malformations, dysmorphic fea tures, abnormalities in growth parameters, neuro logic impairment (including encephalopathy, sei zures or hypotonia) or features suggestive of a metabolic condition. Both parents were required for the consent process and for blood or saliva sampling. Participants were examined by a clin ical geneticist or specialist in metabolics. New borns with suspected chromosomal disorders (e.g., trisomy 18) or conditions thought to be largely non genetic (e.g., fetal alcohol spectrum disorder, diabetic embryopathy) were excluded.
Methods

Participants
Next-generation sequencing and data analysis
We extracted genomic DNA from lymphocytes according to standard methods. The DNA sam ples were enriched for 4813 genes with known associated clinical phenotypes using the Tru Sight One Sequencing Panel kit (Illumina Inc.). This panel includes genes from the Human Gene Mutation Database (www.hgmd.cf.ac.uk/ ac/index.php) and the Online Mendelian Inheri tance in Man database (www.genetests.org), along with other genes identified from commer cially available panels. Enriched libraries were pooled and sequenced in a trio approach (new borns and parents) on the MiSeq instrument (Illumina Inc.), according to the manufacturer's recommendations for pairedend 150 base pair reads. The MiSeq Reporter Software (Illumina Inc.) was used for adaptor trimming, sample demultiplexing and FASTQ file generation.
We used the NextGene software (SoftGen etics LLC) for data processing, alignment, vari ant calling and annotation. The average coverage of the target bases was 97×, with 97.7% of the regions of interest having at least 10× coverage and 95.0% having at least 20× coverage (Appen dix 1, available at www.cmaj.ca/lookup/suppl/ doi:10.1503/cmaj.150823//DC1). We analyzed the nextgeneration sequencing data from each trio under all modes of inheritance (de novo dominant, autosomal dominant, recessive or Xlinked) using the variant comparison tool of the NextGene viewer. The lists of variants were subsequently reduced by filtering out those with a minor allele frequency greater than 1% in either the 1000 Genomes project (February 2012 data release) or the National Heart, Lung and Blood Institute Exome Sequencing Project (Jan uary 2013 data release).
All candidate mutations were inspected visu ally using the NextGene viewer and the Integra tive Genomics viewer (Broad Institute) to exclude obvious falsepositive results. Candi date genes were discussed with the clinicians involved in patient care to assess the importance of genotype-phenotype correlation. Finally, all diseasecausing mutations were confirmed by Sanger sequencing, and segregation was tested in the appropriate family members.
Results
We recruited 20 patients (14 boys and 6 girls) and their parents for this pilot study. The clin ical descriptions of the newborns included in the study are summarized in Table 1 . Of these 20 patients, 10 presented with neurologic signs or symptoms (e.g., hypotonia, seizures), and 6 presented with multiple malformations. Two of the 20 newborns had a family history of a simi lar complex medical presentation, and 3 were born to con sanguineous parents. Of the 20 new borns, 12 were enrolled in this pilot study after discharge from the NICU (retrospective) and 8 were enrolled while admitted to the NICU (pro spective). The clinical investigations under taken for these patients are summarized in Table 2 .
Nextgeneration sequencing provided a molecular diagnosis for 8 of the 20 newborns, for a diagnostic rate of 40%. The diagnoses (and associated genes) were renal tubular dysgenesis (ACE), SCN1Arelated encephalopathy syndrome (SCN1A), Xlinked myotubular myo pathy (MTM1), FTO deficiency syndrome (FTO), cranio ectodermal dysplasia (WDR19), congenital myasthenic syndrome (CHRND), autosomal dominant intellectual disability syndrome type 7 (DYRK1A) and Denys-Drash syndrome (WT1) ( Table 3) .
For 2 of the newborns (cases 8 and 15), standardofcare (nonresearch) sequencing resulted in molecular diagnoses. In case 8, a targeted candidate gene (MTM1) was Sanger sequenced, and in case 15, a nextgeneration sequencing-based panel of genes (n = 18) was sequenced. Both of these tests were performed in an outofcountry clin ical diagnostic labora tory. The diagnostic rate in the consanguineous families was 3 of 3 (100%), although 1 of these newborns had a de novo mutation (case 18).
The time to return of results ranged from 2 to 58 weeks (mean 15.2 wk). The time for return of results was not a primary outcome measure, and the wide variability reflected the limited avail ability of the MiSeq platform for research pur poses. Short case histories for each of the patients with a molecular diagnosis are provided in Appendix 2, available at www.cmaj.ca/lookup/ suppl/doi:10.1503/cmaj.150823//DC1.
Of the 8 patients in this study for whom a diagnosis was made by nextgeneration sequencing, 2 individuals had a change in medi cal management because of the diagnosis. For the patient with ACE mutations (case 2), the molecular diagnosis guided subsequent assess ment of aldosterone and the initiation of fludro cortisone, which ultimately resulted in improved kidney function. 13 In the other patient (case 19), diagnosis of a de novo WT1 mutation altered plans for surgical management. Both kidneys are to be removed during kidney transplant, to reduce the substantial risk of Wilms tumour should the kidneys not be removed. Knowledge of the diagnosis in the other 6 cases provided beneficial information to care providers about the natural history and prognosis and allowed accurate counselling about recurrence risk and prenatal diagnosis.
Interpretation
Nextgeneration sequencing has the potential to rapidly transform the practice of clinical gen etics. In particular, newborns admitted to the NICU with rare and complex diseases may ben efit substantially from a timely molecular diag nosis through nextgeneration sequencing. There are several approaches to nextgeneration sequencing, and we opted to restrict sequencing to a comprehensive panel of genes understood to be diseaserelevant. This choice allowed us to circumvent the challenges associated with mas sive data sets, infrastructure and variant inter pretation. The diagnostic success rate within our study was 40% (8/20), comparable to that achieved with larger cohorts (22%-31%) on the basis of clinical wholeexome sequencing. 9, 10 One of the most important advantages of a focused panel approach is that testing can be performed in a hospitalbased molecular labora tory, using smaller and more affordable next generation sequencing platforms, rather than the larger infrastructure that is often found only in dedicated genomics centres. As such, samples need not be "sent away" or "batched" to outside laboratories; instead, sequencing and analysis Note: DIP = distal interphalangeal joint, DORV = double outlet right ventricle, IUGR = intrauterine growth retardation, PIP = proximal interphalangeal joint, SD = standard deviation, VSD = ventricular septal defect. *Trio = newborn + parents. †Time to return of test results.
can be performed locally, in a potentially shorter time frame, which is of particular importance for the care of critically ill neonates without a diagnosis. This approach also facilitates input and collaboration from the mostresponsible bedside physician, to enable efficient genotypephenotype correlation. The focused panel approach is more consis tent with the local use of microarrays, a test that is often available in tertiary care centres and can be performed with a return of results within days to weeks after blood sampling. Quantita tive fluorescence polymerase chain reaction techniques can also be performed with a rapid return of results when there is suspicion of aneuploidy, such as trisomy 21, 18 or 13.
The Canadian College of Medical Geneticists published a position statement on the clinical application of genomewide sequencing approaches for the clinical care of patients in whom rare diseases are suspected.
14 This state ment recommended that genomewide data be further refined by computerbased filtering to include only those genes relevant to the particular clinical presentation, to minimize the risk of iden tifying an incidental finding (a genetic variant unrelated to the primary indication for testing). In addition, the focused interrogation of selected genes can dramatically reduce the number of vari ants requiring interpretation in the clinical setting. Our diseasefocused nextgeneration sequencing approach, which had 4813 genes, can thus be If we assume that coverage is the same (if not bet ter) with the commercially available panel, a simi lar diagnostic rate can be expected, despite the exclusion of more than 2000 genes. In our study, we did not identify any incidental findings, but the risk of doing so would be minimized by using a refined, panelbased strategy that is tailored spe cifically for the NICU. The feasibility of nextgeneration sequencing in the NICU and its diagnostic success rate have yet to be extensively studied in a prospective manner, and there are multiple approaches that could be used for such future studies. If suitable resources are available, wholegenome sequenc ing can provide a comprehensive test and rapid generation of data. This approach was studied in another NICU setting, with confirmation of diag nosis in 2 days in a retrospective sample of 2 children with a known genetic disease. 15 Addi tional diagnoses were possible in NICU inpa tients when parents were included in the test ing. 15 In a study of wholegenome sequencing in children retrospectively identified after an inpa tient stay in either the neonatal or pediatric inten sive care unit, a diagnosis was achieved in 57% (20/35) of cases. 11 These wholegenome sequencing studies required highthroughput sequencers, bioinformatics support, automation and experts in the field of translational genomics, resources that are not readily available to most diagnostic laboratories at this time. Another option, wholeexome sequencing, focuses on the protein coding regions of the approximately 22 000 human genes. However, interpretation of variants identified by wholeexome and wholegenome sequencing can be a challenge in a clinical setting, because threequarters of the known genes assessed are not associated with human disease. There is less uniform coverage in wholeexome sequencing, and up to 10% of the region of interest may not be adequately covered. 16 Thus, although whole exome and wholegenome sequencing are amen able to novel gene discovery, the time frame required for characterization and validation of a novel gene is often too long to be of practical help for sick neonates.
Limitations
This pilot project involved a small sample of 20 patients who were highly selected for admis sion to the NICU for genetic causes. Further study will include testing in expanded cohorts to evaluate diagnostic rates for the varied clinical presentations seen in the NICU. Determination of the clinical presentations best served by next generation sequencing in the NICU will be help ful for future testing.
An assessment of the timing of return of results as a primary outcome measure was not part of the current study but would also be beneficial, as this factor may substantially affect patient care. Simi larly, an evaluation of the "best time" to pursue nextgeneration sequencing is needed, to decide whether this method should be used as a firsttier test in the NICU or as a final investigation in an outpatient clinic. An expanded sample of patients, identified consecutively, prospectively and with appropriate controls, will help to answer the ques tions of who should be offered nextgeneration sequencing, and when.
Conclusion
The results of this study highlight the potential impact of nextgeneration sequencing on both patient care and health care systems. Insurers are faced with increasing costs of genetic testing because of rapidly expanding knowledge about the genetic causes of rare diseases. A single, targeted, diseaserelevant panel, such as the one used here, could potentially address the testing needs for a sick child at a fraction of the current cost. The availability and accessibility of approaches similar to the one reported here could also strongly affect the timing of health care delivery. Improving the time to diagnosis could substantially alter the role of medical genetics in acute management.
